Company record · updated August 5, 2026
MapLight Therapeutics, Inc.: 6 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs September 19, 2025 to September 19, 2025.
6observations
1source filings
6verified rows
2025-09-19most recent as-of date
Source rails for this company: S-1 charter round (6).
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2025-09-19 | Series D price per share | 0.9522 USD | — | VERIFIED | "Original Issue Price" defined for Series D | 000119312525209084 |
| 2025-09-19 | Series C price per share | 1.5272 USD | — | VERIFIED | "Original Issue Price" defined for Series C | 000119312525209084 |
| 2025-09-19 | Series B-1 price per share | 2.596 USD | — | VERIFIED | "Original Issue Price" defined for Series B-1 | 000119312525209084 |
| 2025-09-19 | Series B price per share | 1.1775 USD | — | VERIFIED | "Original Issue Price" defined for Series B | 000119312525209084 |
| 2025-09-19 | Series A-1 price per share | 1.0705 USD | — | VERIFIED | "Original Issue Price" defined for Series A-1 | 000119312525209084 |
| 2025-09-19 | Series A price per share | 1 USD | — | VERIFIED | "Original Issue Price" defined for Series A | 000119312525209084 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.